VIVUS (VVUS) Expands Management Team Ahead of Expected Qnexa Approval
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS), has added several key employees and expansion of the senior management team in anticipation of the commercialization of Qnexa, if approved. New hires in the commercial group include Chris Thompson as national sales director and Alfred Tenuto as senior director of market access. VIVUS has also added Santosh T. Varghese, M.D., as vice president of medical affairs. Barbara Troupin, M.D., MBA, has been promoted to vice president, scientific communication & risk management, and Timothy E. Morris will continue in his role as chief financial officer and will assume responsibility for business development as senior vice president global corporate development and finance. VIVUS has also expanded executive management in its clinical group with the addition of Roman V. Dvorak, M.D., Ph.D, who will serve as senior director, clinical development.
More detail from the release:
Chris Thompson joins VIVUS as the national sales director after a successful 23-year career with Amgen, most recently as the vice president, sales of the Bone Health Business Unit. In this role, Mr. Thompson recruited and managed a team of over 545 employees, including 500 endocrine and primary care sales representatives. During his career at Amgen, Mr. Thompson rose through the ranks from a field sales representative to executive management positions. In addition, he has sales and sales management experience with Baxter International and Johnson & Johnson.
Alfred Tenuto joins VIVUS as the senior director of market access after a successful 13-year career with Eli Lilly & Company, most recently as director of trade. In this role, Mr. Tenuto was responsible for the distribution network and relationships with wholesalers and specialty pharmacies. At VIVUS, he will manage the Qnexa distribution network and be responsible for Federal and State public policy and reimbursement with private third party payors. In addition, he has pharmaceutical market access, pharmacy and national accounts experience with ALZA.
Dr. Varghese joins VIVUS as vice president medical affairs. Dr. Varghese comes from Elan Corporation, where he was responsible for the global and U.S. medical affairs bio-neurology therapeutic group for Tysabri. Prior to Elan, he built and led medical affairs teams responsible for large brands, such as Allegra and Nasacort at Aventis/Sanofi-Aventis; Clarinex/Claritin, Nasonex, Integrilin, Zetia, Vytorin, and other compounds within Schering-Plough/Merck. At VIVUS, he will establish the medical affairs group for Qnexa and will provide scientific and medical brand strategy to the commercial team. In addition, he will supervise and provide direction to field based teams and assume responsibility for safety and interaction with the FDA.
Roman V. Dvorak M.D., PhD will serve as the senior director, clinical development. Dr. Dvorak brings to VIVUS more than 15 years of clinical research experience, both in academia and the industry. He has worked in various clinical development and medical affairs positions with Johnson & Johnson, Pfizer, Tercica and Leptos Biomedical. His research as well as drug development work has focused on the area of metabolic diseases, particularly obesity and diabetes. He has designed and implemented clinical studies from Phase 1 to Phase 4, including large international registration trials.
Dr. Troupin has been promoted to the newly created position of vice president of scientific communication and risk management. Dr. Troupin has been vice president of scientific communication and risk management since February 2012. Prior to that, she held senior director roles in medical affairs and in clinical development at VIVUS, initially joining the company in April 2006. Before joining VIVUS, Dr. Troupin was the medical director for Profil Institute for Clinical Research in San Diego, a niche Phase 1 site focused on complex clinical trials in diabetes and obesity. Prior to that she was the medical director for Radiant Research in San Diego for five years and was the principal investigator on more than 150 cardiovascular and metabolic clinical studies. In her new role, Dr. Troupin will supervise development of publications and presentations, advise in the development of Scientific Symposia and Advisory Boards, and establish and support communications with medical and scientific key opinion leaders and advocates. In addition, she will take responsibility for the implementation of the Risk Evaluation and Mitigation Strategies (REMS) for Qnexa.
In addition to his current role as senior vice president finance and chief financial officer, Mr. Morris assumes responsibility for global corporate development, including partnering efforts for Qnexa and avanafil.
More detail from the release:
Chris Thompson joins VIVUS as the national sales director after a successful 23-year career with Amgen, most recently as the vice president, sales of the Bone Health Business Unit. In this role, Mr. Thompson recruited and managed a team of over 545 employees, including 500 endocrine and primary care sales representatives. During his career at Amgen, Mr. Thompson rose through the ranks from a field sales representative to executive management positions. In addition, he has sales and sales management experience with Baxter International and Johnson & Johnson.
Alfred Tenuto joins VIVUS as the senior director of market access after a successful 13-year career with Eli Lilly & Company, most recently as director of trade. In this role, Mr. Tenuto was responsible for the distribution network and relationships with wholesalers and specialty pharmacies. At VIVUS, he will manage the Qnexa distribution network and be responsible for Federal and State public policy and reimbursement with private third party payors. In addition, he has pharmaceutical market access, pharmacy and national accounts experience with ALZA.
Dr. Varghese joins VIVUS as vice president medical affairs. Dr. Varghese comes from Elan Corporation, where he was responsible for the global and U.S. medical affairs bio-neurology therapeutic group for Tysabri. Prior to Elan, he built and led medical affairs teams responsible for large brands, such as Allegra and Nasacort at Aventis/Sanofi-Aventis; Clarinex/Claritin, Nasonex, Integrilin, Zetia, Vytorin, and other compounds within Schering-Plough/Merck. At VIVUS, he will establish the medical affairs group for Qnexa and will provide scientific and medical brand strategy to the commercial team. In addition, he will supervise and provide direction to field based teams and assume responsibility for safety and interaction with the FDA.
Roman V. Dvorak M.D., PhD will serve as the senior director, clinical development. Dr. Dvorak brings to VIVUS more than 15 years of clinical research experience, both in academia and the industry. He has worked in various clinical development and medical affairs positions with Johnson & Johnson, Pfizer, Tercica and Leptos Biomedical. His research as well as drug development work has focused on the area of metabolic diseases, particularly obesity and diabetes. He has designed and implemented clinical studies from Phase 1 to Phase 4, including large international registration trials.
Dr. Troupin has been promoted to the newly created position of vice president of scientific communication and risk management. Dr. Troupin has been vice president of scientific communication and risk management since February 2012. Prior to that, she held senior director roles in medical affairs and in clinical development at VIVUS, initially joining the company in April 2006. Before joining VIVUS, Dr. Troupin was the medical director for Profil Institute for Clinical Research in San Diego, a niche Phase 1 site focused on complex clinical trials in diabetes and obesity. Prior to that she was the medical director for Radiant Research in San Diego for five years and was the principal investigator on more than 150 cardiovascular and metabolic clinical studies. In her new role, Dr. Troupin will supervise development of publications and presentations, advise in the development of Scientific Symposia and Advisory Boards, and establish and support communications with medical and scientific key opinion leaders and advocates. In addition, she will take responsibility for the implementation of the Risk Evaluation and Mitigation Strategies (REMS) for Qnexa.
In addition to his current role as senior vice president finance and chief financial officer, Mr. Morris assumes responsibility for global corporate development, including partnering efforts for Qnexa and avanafil.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Virtus Investment Partners names Jack Boyce to its board
- LiveRamp shrinks board to six directors after resignation
Create E-mail Alert Related Categories
Corporate News, FDA, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
